Drug intelligence / Profile preview

OC601

Development stage: Unknown
Lead developer: Oncocross
Modality: Small Molecules
Administration: Oral

Overview

OC601 is an investigational small molecule drug candidate being developed by Oncocross for the treatment of COVID-19. Discovered using the company's proprietary RAPTOR AI™ platform, the drug was identified through transcriptomic screening to find compounds that can normalize gene expression signatures associated with SARS-CoV-2 infection. OC601 is a repositioned drug candidate, meaning it is an existing compound being explored for a new therapeutic indication. It has entered Phase 1 clinical trials in Australia (ACTRN12621001111808) to assess its safety, tolerability, and pharmacokinetic profile in healthy volunteers. The specific molecular target and mechanism of action of OC601 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on OC601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC601.

Explore the full profile